<DOC>
	<DOCNO>NCT00266552</DOCNO>
	<brief_summary>The purpose study assess effectiveness safety oral solution risperidone ( antipsychotic medication ) versus placebo treatment conduct disorder child mild , moderate , borderline mental retardation .</brief_summary>
	<brief_title>A Study Safety Effectiveness Risperidone Versus Placebo Treatment Conduct Disorder Children With Mild , Moderate , Borderline Mental Retardation</brief_title>
	<detailed_description>Conduct psychiatric disorder find among high proportion people mental retardation among people mentally retarded . Among many different treatment approach conduct disorder drug therapy , behavioral treatment , psychotherapy , train cognitive social skill . Studies suggest neuroleptic drug , risperidone , may beneficial treat conduct disorder mental retardation . This randomized , double-blind , placebo-controlled study evaluate effectiveness risperidone ( 0.02 0.06 mg/kg/day ) compare placebo treatment child 5 12 year age mild , moderate , borderline mental retardation , display destructive behavior . The study two phase : run-in phase 1 week treatment phase 6 week . Patients receive placebo take orally day first week ( run-in ) . On basis score Nisonger Child Behavior Rating Form ( N-CBRF ) Vineland Adaptive Behavior Scale first week , patient either continue double-blind treatment phase discontinue study . During treatment phase patient receive oral solution risperidone ( increase gradually maximum dose 0.06 mg/kg ) placebo take daily 6 week . A parent caregiver evaluate child 's behavior symptom schedule office visit course treatment . The primary measure effectiveness change Conduct Problem subscale Nisonger Child Behavior Rating Form ( N-CBRF ) end treatment compare baseline . Additional assessment effectiveness include : Aberrant Behavior Checklist ( ABC ) , Behavioral Problems Inventory ( BPI ) , Clinical Global Impression ( CGI ) . Safety assessment include incidence adverse event throughout study ; weekly measurement vital sign ( pulse , temperature , blood pressure ) evaluation presence severity extrapyramidal symptom Extrapyramidal Symptom Rating Scale ( ESRS ) ; clinical laboratory test perform study initiation end treatment . The study hypothesis risperidone well tolerated effective treatment conduct disorder child age 5 12 year mild , moderate , borderline mental retardation . Risperidone oral solution 1 mg/mL placebo oral solution , daily Days 1 2 dose 0.01 mg/kg body weight . Dose 0.02 mg/kg Day 3 , increase gradually 0.06 mg/kg ( maximum ) daily 6 week . Dosage may increase decreased investigator 's discretion .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Mental Disorders</mesh_term>
	<mesh_term>Problem Behavior</mesh_term>
	<mesh_term>Conduct Disorder</mesh_term>
	<mesh_term>Attention Deficit Disruptive Behavior Disorders</mesh_term>
	<mesh_term>Risperidone</mesh_term>
	<criteria>Diagnosis Conduct Disorder , Oppositional Defiant Disorder , Disruptive Behavior Disorder otherwise specify , Diagnostic Statistical Manual Mental Disorders , 4th edition ( DSMIV ) , Axis I criteria ( patient conduct disorder also meet DSMIV criterion Attention Deficit/Hyperactivity Disorder ( AD/HD ) eligible ) total rating &gt; =24 Nisonger Child Behavior Rating Form ( NCBRF ) Conduct Problem Subscale Diagnosis Mild Mental Retardation , Moderate Mental Retardation Borderline Intellectual Functioning DSMIV Axis II criterion ( represent intelligence quotient ( IQs ) range 35 84 ) Vineland Adaptive Behavior Scale &lt; =84 . Diagnosis Pervasive Development Disorder Schizophrenia and/or Other Psychotic Disorders DSMIV criterion mental impairment cause head injury seizure disorder currently require medication history tardive dyskinesia ( complication neuroleptic therapy involve involuntary movement facial muscle ) neuroleptic malignant syndrome ( rare psychotropicdrug reaction , may characterize confusion , reduce consciousness , high fever pronounce muscle stiffness ) know hypersensitivity , intolerance , unresponsiveness risperidone .</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>12 Years</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>conduct disorder</keyword>
	<keyword>oppositional defiant disorder</keyword>
	<keyword>disruptive behavior disorder otherwise specify</keyword>
	<keyword>ADHD</keyword>
	<keyword>risperidone</keyword>
	<keyword>antipsychotropic agent</keyword>
	<keyword>child</keyword>
</DOC>